Please ensure Javascript is enabled for purposes of website accessibility

Why Hazy Accounting Caused This Marijuana Stock To Tumble Today

By Todd Campbell - Jan 11, 2016 at 4:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A lack of confidence in its financial process is leading investors to head for the exits.

Source: GW Pharmaceuticals plc

What: After a story appeared in The Sunday Times regarding the company's admission in filings to lacking accounting controls, shares in GW Pharmaceuticals plc (GWPH) slumped by 10% earlier this morning before recovering to a loss of 7.15% at 3 p.m. EST.

So what: Last week, the company disclosed that it had a material weakness in its accounting practices for the year ending Sept. 30.

The disclosure was made to comply with stricter disclosure policies in the U.S. and the admission highlights a material weakness in controls related to the accounting of clinical trial costs and milestone liabilities.

Now what: It's never a good sign when a company begins questioning its own internal financial controls and the revelation is the latest in a string of stumbles at the company last year.

Previously, GW Pharmaceuticals had disclosed the failure of three phase 3 trials of its THC drug Sativex for cancer pain and a disappointing mid stage trial readout for the treatment of schizophrenia.

GW Pharmaceuticals indicated that it doesn't expect to have to restate financials because of the material weakness, but it does admit that it is a possibility.

Given the company is spending millions of dollars on trials to evaluate the potential of marijuana medicine, including expenses related to late stage trials in epilepsy that will have data available soon, this company has its hands full. Until we know for certain that its financials are ship-shape, this stock is too risky for me to be a buyer -- especially ahead of the upcoming epilepsy results. Therefore, the sidelines are probably a good place to be in this one until there's more clarity. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.